Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Sees Significant Decrease in Short Interest

Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) was the recipient of a significant decline in short interest in April. As of April 30th, there was short interest totaling 200 shares, a decline of 100.0% from the April 15th total of 705,600 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ? days.

Shanghai Junshi Biosciences Stock Performance

OTCMKTS:SHJBF opened at C$3.35 on Wednesday. Shanghai Junshi Biosciences has a twelve month low of C$2.99 and a twelve month high of C$4.23. The company has a 50-day moving average of C$3.01 and a 200-day moving average of C$3.34.

Shanghai Junshi Biosciences Company Profile

Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.

Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.